Icomidocholic Acid
drugOn this page
Also known as Acide icomidocholiqueAcido icomidocolicoArachidyl amido cholanoic acidAramchol
Summary
Icomidocholic Acid (CHEMBL4297262) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 6 conditions
- Clinical trials: 11
- Chemistry: 702.1 Da · C44H79NO5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297262 |
| Name | Icomidocholic Acid |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 18738120 |
| Molecular formula | C44H79NO5 |
| Molecular weight | 702.1 |
| InChIKey | SHKXZIQNFMOPBS-OOMQYRRCSA-N |
SMILES: CCCCCCCCCCCCCCCCCCCC(=O)N[C@H]1CC[C@]2([C@@H](C1)C[C@H]([C@@H]3[C@@H]2C[C@@H]([C@]4([C@H]3CC[C@@H]4[C@H](C)CCC(=O)O)C)O)O)C
IUPAC name: (4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-dihydroxy-3-(icosanoylamino)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
Also known as: Acide icomidocholique, Acido icomidocolico, Arachidyl amido cholanoic acid, Aramchol, Icomidocholic acid, ICOMIDOCHOLIC ACID
Parent form; salt/anhydrous children: CHEMBL6068507
Patent coverage: 381 distinct patent families (1,200 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| metabolic dysfunction-associated steatohepatitis | 3 | MONDO:0007027 | EFO:1001249 |
| metabolic dysfunction-associated steatotic liver disease | 3 | MONDO:0013209 | EFO:0003095 |
| gallstones | 2 | MONDO:0005346 | EFO:0004210 |
| fatty liver disease | 2 | MONDO:0004790 | HP:0001397 |
| cirrhosis of liver | 2 | MONDO:0005155 | EFO:0001422 |
| liver disorder | 1 | MONDO:0005154 | EFO:0001421 |
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 7 |
| PHASE2 | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01094158 | PHASE2 | COMPLETED | Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis |
| NCT02279524 | PHASE2 | COMPLETED | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH |
| NCT02325492 | PHASE2 | TERMINATED | Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study |
| NCT02684591 | PHASE2 | COMPLETED | Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy |
| NCT07251712 | PHASE1 | RECRUITING | Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet |
| NCT00776841 | PHASE1 | COMPLETED | A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers |
| NCT02374437 | PHASE1 | COMPLETED | Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers |
| NCT02803996 | PHASE1 | COMPLETED | Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers |
| NCT03760848 | PHASE1 | COMPLETED | Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers |
| NCT03774173 | PHASE1 | COMPLETED | Comparison of Aramchol Concentrations With Once or Twice Daily Dosing |
| NCT05874336 | PHASE1 | COMPLETED | An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).